Wordt geladen...
Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone
The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical landscape of prostate cancer treatment. Both drugs were designed to further suppress androgen receptor (AR) signaling, which is restored following first-line androgen deprivation therapies. Resistance to enzalutamide...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer US
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4167475/ https://ncbi.nlm.nih.gov/pubmed/25048254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12672-014-0190-1 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|